Biohaven (BHVN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The drug developer's research spending fell to $101.9 million, but an FDA hold on new opakalim enrollment hangs over its biggest licensing deal.
SEC Filings
The drugmaker says licensing payments from SK Biopharmaceuticals could later let it release a significant part of the reserve.
Earnings
The agency will also convene an advisory committee on troriluzole, a second step before any approval decision, Biohaven said.
SEC Filings
An 8-K shows up to $100 million in near-term payments plus royalties of approximately 20%, with Biohaven keeping US, European and Chinese rights.